Breaking News

Biovitrum Wins Phase III Contract

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biovitrum has entered an agreement with Resistentia Pharmaceuticals for process development and manufacturing of the biopharmaceutical substance RES 08 intended for use in Phase III trials of Resistentia’s new protein-based drug candidate for the treatment of allergy. RES 08 works by blocking the effect of IgE, preventing an allergic reaction and is intended for the treatment of IgE-mediated allergies. Biovitrum’s assignment is to develop the existing process for the biotechnica...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters